Literature DB >> 23321561

Tryptanthrin derivatives as Toxoplasma gondii inhibitors--structure-activity-relationship of the 6-position.

Bogdana Krivogorsky1, Amber C Nelson, Kelsi A Douglas, Peter Grundt.   

Abstract

A panel of derivatives of the natural product tryptanthrin was synthesized and screened for its in vitro activity against the intracellular parasite Toxoplasma gondii. We concentrated on the modification of the 6-keto group of tryptanthrin and prepared a series of oximes, hydrazones and alcohols based on tryptanthrin. We evaluated parasite growth inhibition and host cell cytotoxicity. Our results indicate that in particular alcohol analogs are promising candidates for further investigation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23321561     DOI: 10.1016/j.bmcl.2012.12.024

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Tryptanthrin derivatives as efficient singlet oxygen sensitizers.

Authors:  Daniela Pinheiro; Marta Pineiro; J Sérgio Seixas de Melo
Journal:  Photochem Photobiol Sci       Date:  2021-11-04       Impact factor: 4.328

Review 2.  Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.

Authors:  Madalyn M McFarland; Sydney J Zach; Xiaofang Wang; Lakshmi-Prasad Potluri; Andrew J Neville; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

3.  Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Andrei S Potapov; Anastasia R Kovrizhina; Vladislava V Matveevskaya; Maxim L Belyanin; Dmitriy N Atochin; Svitlana O Zanoza; Nadiya M Gaidarzhy; Sergiy A Lyakhov; Liliya N Kirpotina; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2018-10-12       Impact factor: 6.514

4.  Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis.

Authors:  Katarzyna Dzitko; Agata Paneth; Tomasz Plech; Jakub Pawełczyk; Lidia Węglińska; Piotr Paneth
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

5.  Synthesis and in vitro evaluation of antitumor activity of spiro[indolo[2,1-b]quinazoline-pyrano[2,3-d]pyrimidine] and spiro[indolo[2,1-b]quinazoline-pyrido[2,3-d]pyrimidine] derivatives by using 2D and 3D cell culture models.

Authors:  Zahra Sadeghian; Mohammad Bayat; Fatemeh Safari
Journal:  Mol Divers       Date:  2022-01-19       Impact factor: 2.943

Review 6.  Drugs in development for toxoplasmosis: advances, challenges, and current status.

Authors:  P Holland Alday; Joseph Stone Doggett
Journal:  Drug Des Devel Ther       Date:  2017-01-25       Impact factor: 4.162

Review 7.  Oxidative Stress as a Possible Target in the Treatment of Toxoplasmosis: Perspectives and Ambiguities.

Authors:  Karolina Szewczyk-Golec; Marta Pawłowska; Roland Wesołowski; Marcin Wróblewski; Celestyna Mila-Kierzenkowska
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.